# About BPC-157 Meds — Editorial Standards and Publisher Information > About BPC-157 Meds: an independent editorial project that publishes summaries of the BPC-157 peer-reviewed research literature. Editorial standards, sourcing methodology, and disclaimer. BPC-157 Meds publishes summaries of the peer-reviewed research literature on BPC-157 alongside the compound's current regulatory and compounding status. We are not a clinic, a pharmacy, or a vendor. ## What this site is BPC-157 Meds is an independent editorial project that publishes summaries of the peer-reviewed research literature on BPC-157 (Body Protection Compound 157). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The modifier 'meds' in the domain name is editorial framing — a position the publisher occupies relative to the literature. BPC-157 is currently under active regulatory evaluation for potential inclusion on the FDA's 503A Bulks List for compounding pharmacies. That evaluation — the PCAC hearing scheduled for July 2026, the April 2026 Category 2 removal, the WADA S0 prohibition since 2022 — is precisely the 'meds' context this site covers. It is a statement about the regulatory and scientific present, not a service or product the site offers. We do not have a physical address, a phone number, or a clinic location. We do not refer readers to any specific vendor, compounding pharmacy, or prescriber. We have no clinical staff. ## Editorial standards and sourcing methodology Every quantitative claim on this site cites a peer-reviewed source. The citation standard for this site is: - **Primary sources preferred:** Original research studies in peer-reviewed journals (Journal of Orthopaedic Research, Biomedicines, Frontiers in Pharmacology, Medicina, etc.) are the primary citation layer. - **Reviews and systematic reviews** (McGuire et al. 2025, Vasireddi et al. 2025, Seiwerth et al. 2021) are cited where they synthesize primary evidence — not to replace primary sources, but to place them in context. - **Expert commentary** (Whitehouse 2025, Inflammopharmacology) is cited where it provides context on regulatory and mechanistic interpretation, clearly labeled as commentary. - **No invented claims:** No claim appears on this site that is not traceable to a published source in the references index. Dose values, half-life numbers, percent outcomes, and mechanistic pathway descriptions all cite specific studies. - **Regulatory data:** FDA and WADA status information is drawn from published regulatory notices, official WADA documentation, and secondary sources in clinical literature that cite primary regulatory actions. We acknowledge the limitations of the BPC-157 evidence base: most preclinical work originates from a single Zagreb research group, no randomized controlled human trials have been published, and the Phase 2 IBD trial results (Pliva) were never published in peer review. We do not suppress these limitations — they appear explicitly in the Research and FAQ sections. Language on this site describes research findings, not clinical recommendations. Phrasing is consistently: 'studied at X in [species]', 'preclinical models showed', 'research suggests' — never 'an effective dose is', 'you should take', or 'this compound treats'. ## The regulatory timeline for BPC-157 Because BPC-157's regulatory status is a primary focus of this site, the key timeline is worth stating precisely: **September 2023:** FDA placed BPC-157 on the 503A Category 2 list, effectively prohibiting compounding pharmacies operating under 503A of the FDCA from producing it. **April 2026:** FDA removed BPC-157 (and TB-500) from the 503A Category 2 list following withdrawal of their nominations. Neither compound was placed on Category 1 (the permitted 503A Bulks List). Status moved to a regulatory gray zone: not explicitly prohibited, not authorized. **July 2026:** FDA Pharmacy Compounding Advisory Committee (PCAC) scheduled formal review of BPC-157 free base and BPC-157 acetate for potential inclusion on the 503A Bulks List. The nominated use case is ulcerative colitis. The outcome of this review is not known as of this publication. **Since 2022:** BPC-157 has been prohibited by WADA under Section S0 — Non-Approved Substances. This prohibition is independent of the FDA compounding regulatory status. **At no point:** BPC-157 has had an IND (Investigational New Drug) application filed in the United States, FDA approval for any human indication, or a USP/NF monograph. ## Editorial scope and disclaimer BPC-157 Meds publishes editorial commentary on publicly available research. Nothing on this site constitutes medical advice, a diagnosis, or a treatment recommendation. No reader should alter their medical care based on content published here. BPC-157 is not approved for human use by the FDA or any major regulatory agency. It is classified as a research chemical. It is prohibited by WADA under Section S0. Readers with clinical questions about BPC-157 or any related compound should consult a licensed healthcare provider. This site is an independent editorial digest — no products, no clinical services, no vendor referrals. --- An independent editorial digest of the peer-reviewed BPC-157 research record.